About the authors
Махмудова Майя Рафиковна, кандидат медицинских наук, врач методист организационно-методического отдела Республиканского Центра Переливания крови МЗ, Ташкент Республика Узбекистан
Makhmudova Maya Rafikovna, candidate of medical sciences, physician methodologist of the organizational and methodological department of the Republican Center for Blood Transfusion of the Ministry of Health, Tashkent, Republic of Uzbekistan
Махмудова Майя Рафиковна, медицина илимдеринин кандидаты, Саламаттык сактоо министрлигинин Республикалык кан куюу борборунун уюштуруу-методикалык бөлүмүнүн врач-методисти, Өзбекстан Республикасы, Ташкент шаары.
References
1. Essays on industrial and clinical transfusiology / edited by A.I. Vorobyov. – M.: Newdiamed, 2006. – 632 p.
2. Practical transfusiology / edited by G.I. Kozinets. – M.: Practical medicine, 2005. – 544 p.
3. Bulanov A.Yu., Gorodetsky V.M. Protocol of infusion therapy in patients with hemoblastosis // Programmatic treatment of dise
ases of the blood system / ed. V.G. Savchenko. – M.: Praktika, 2012.
4. Galstyan G.M., Gorodetsky V.M. Monitoring the adequacy and safety of infusion therapy: possibilities and limitations // Infu
sion-transfusion therapy in clinical medicine / edited by B.R. Gelfand. –M.: LLC "Medical Information Agency", 2009. – pp.46-
69.
5. Dellinger RP, Levy MM, Rhodes A. et al. Surviving sepsis campaign:international guidelines for management of severe sepsis
and septic shock: 2012. Crit Care Med. 2013 Feb; 41(2):580-637 с.
6. FDA: Fatalities reported to FDA following blood collection and transfusion: Annual Summary for Fiscal Year 2018. Silver Spri
ng, MD, US Food and Drug Administration, 2018.
7. Holcomb JB, Tilley BC, Baraniuk S, et al: Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mor
tality in patients with severe trauma: the PROPPR randomized clinical trial. JAMA 313(5):471–482, 2015. doi: 10.1001/ jama.
2015.12
1. Essays on industrial and clinical transfusiology / edited by A.I. Vorobyov. – M.: Newdiamed, 2006. – 632 p.
2. Practical transfusiology / edited by G.I. Kozinets. – M.: Practical medicine, 2005. – 544 p.
3. Bulanov A.Yu., Gorodetsky V.M. Protocol of infusion therapy in patients with hemoblastosis // Programmatic treatment of dise
ases of the blood system / ed. V.G. Savchenko. – M.: Praktika, 2012.
4. Galstyan G.M., Gorodetsky V.M. Monitoring the adequacy and safety of infusion therapy: possibilities and limitations // Infu
sion-transfusion therapy in clinical medicine / edited by B.R. Gelfand. –M.: LLC "Medical Information Agency", 2009. – pp.46-
69.
5. Dellinger RP, Levy MM, Rhodes A. et al. Surviving sepsis campaign:international guidelines for management of severe sepsis
and septic shock: 2012. Crit Care Med. 2013 Feb; 41(2):580-637 с.
6. FDA: Fatalities reported to FDA following blood collection and transfusion: Annual Summary for Fiscal Year 2018. Silver Spri
ng, MD, US Food and Drug Administration, 2018.
7. Holcomb JB, Tilley BC, Baraniuk S, et al: Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mor
tality in patients with severe trauma: the PROPPR randomized clinical trial. JAMA 313(5):471–482, 2015. doi: 10.1001/ jama.
2015.12
1. Essays on industrial and clinical transfusiology / edited by A.I. Vorobyov. – M.: Newdiamed, 2006. – 632 p.
2. Practical transfusiology / edited by G.I. Kozinets. – M.: Practical medicine, 2005. – 544 p.
3. Bulanov A.Yu., Gorodetsky V.M. Protocol of infusion therapy in patients with hemoblastosis // Programmatic treatment of dise
ases of the blood system / ed. V.G. Savchenko. – M.: Praktika, 2012.
4. Galstyan G.M., Gorodetsky V.M. Monitoring the adequacy and safety of infusion therapy: possibilities and limitations // Infu
sion-transfusion therapy in clinical medicine / edited by B.R. Gelfand. –M.: LLC "Medical Information Agency", 2009. – pp.46-
69.
5. Dellinger RP, Levy MM, Rhodes A. et al. Surviving sepsis campaign:international guidelines for management of severe sepsis
and septic shock: 2012. Crit Care Med. 2013 Feb; 41(2):580-637 с.
6. FDA: Fatalities reported to FDA following blood collection and transfusion: Annual Summary for Fiscal Year 2018. Silver Spri
ng, MD, US Food and Drug Administration, 2018.
7. Holcomb JB, Tilley BC, Baraniuk S, et al: Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mor
tality in patients with severe trauma: the PROPPR randomized clinical trial. JAMA 313(5):471–482, 2015. doi: 10.1001/ jama.
2015.12
